Atty. Dkt.: 620-149 Assistant Commissioner for Patents Washington, D.C. 20231 jc912 U.s. Date: July 9, 2001 Sir: Attached for filing is the patent application of: Inventor: LaThangue PEPTIDE ANTAGONISTS OF DP TRANSCRIPTION FACTORS Entitled: and including attachments as noted below: Newly executed Declaration, ⊠ Copy of Declaration from prior application, ☐ Abstract pages of specification and claims (including 20 numbered claims), and 46 sheets of accompanying drawing/s. Record the attached assignment and return to the undersigned. Attached is a Power of Attorney. Priority is hereby claimed under 35 U.S.C. § 119 based on the following foreign applications: Day/Month/Year Filed Country **Application Number** 20 December 1996 Great Britain 9626589.7 22 December 1997 PCT/GB97/03506 , respectively, the entire content of which is hereby incorporated by reference in this application... Certified copy(ies) of foreign application(s) is/are attached. in prior appln. no. Certified copy(ies) filed on Please amend the specification by inserting the following paragraph before the first line: --This application claims , the entire content of which is hereby incorporated by , filed the benefit of Provisional Application No. reference in this application .--Please amend the specification by inserting the following paragraph before the first line: --This application is a 🛛 continuation/ division/ continuation-in-part of Application No. 09/308,935, filed May 27, 1999, , the entire content of which is hereby incorporated by reference in this application .--Petition filed in prior application to extend its life to insure co-pendency. The prior application is assigned to Prolifix Limited. It is hereby requested that the Examiner consider the art cited in the parent application by applicant and/or the Examiner for the reasons stated therein. A listing of that art is attached. "Small entity" statement attached. Applicant claims "small entity" status. Please enter the attached and/or below preliminary amendment prior to calculation of filing fee: Also attached:⊠ Information Disclosure Statement; ☐ Non-Publication Request; ⊠ Nucleotide area/or Amino Acid Sequence Submission; ☐ Statement deleting Inventor(s) named in prior application; ☒ Other: 3 sheets of formal drawings; Abstract FILING FEE IS BASED ON CLAIMS AS FILED LESS ANY HEREWITH CANCELED 710.00 Basic Filing Fee \$ - 20 (at least 20) = \$ 0.00 0 x \$ 18.00 Total effective claims 20 \$ 0.00 0 x\$ 80.00 1 - 3 (at least 3) = Independent claims If any proper multiple dependent claims now added for first time, add \$270.00 (ignore improper) 0.00 \$ **SUBTOTAL** 710.00 \$ If "small entity," then enter half (1/2) of subtotal and subtract 0.00)SECOND SUBTOTAL 710.00 0.00 Assignment Recording Fee (\$40.00) **TOTAL FEE ENCLOSED \$** 710.00 Any future submission requiring an extension of time is hereby stated to include a petition for such time extension.

The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor Arlington, Virginia 22201-4714 Telephone: (703) 816-4000 Facsimile: (703) 816-4100 BJS:eaw

Signature:

**NIXON & VANDERHYE P.C.** 

By Atty: B. J. Sadoff, Reg. No. 36,663

IN THE UNITED STATES PATENT AND TRADEMARK SEFICE

Assistant Commissioner for Patents

Washington, D.C. 20231

Date: July 9, 2001

Sir:

Attached for filing is the patent application of: Inventor: LaThangue Entitled: PEPTIDE ANTAGONISTS OF DP TRANSCRIPTION FACTORS and including attachments as noted below: Newly executed Declaration, Copy of Declaration from prior application, Abstract 46 pages of specification and claims (including 20 numbered claims), and sheets of accompanying drawing/s. Record the attached assignment and return to the undersigned. Attached is a Power of Attorney. Priority is hereby claimed under 35 U.S.C. § 119 based on the following foreign applications: **Application Number** Country Day/Month/Year Filed 9626589.7 Great Britain 20 December 1996 PCT/GB97/03506 22 December 1997 , respectively, the entire content of which is hereby incorporated by reference in this application... Certified copy(ies) of foreign application(s) is/are attached. Certified copy(ies) filed on in prior appln. no. Please amend the specification by inserting the following paragraph before the first line: --This application claims the benefit of Provisional Application No. . filed , the entire content of which is hereby incorporated by reference in this application .--Please amend the specification by inserting the following paragraph before the first line: --This application is a 🛛 continuation/ division/ continuation-in-part of Application No. 09/308,935, filed May 27, 1999. , the entire content of which is hereby incorporated by reference in this application.--Petition filed in prior application to extend its life to insure co-pendency. The prior application is assigned to Prolifix Limited. It is hereby requested that the Examiner consider the art cited in the parent application by applicant and/or the Examiner for the reasons stated therein. A listing of that art is attached. Applicant claims "small entity" status. "Small entity" statement attached. Please enter the attached and/or below preliminary amendment prior to calculation of filing fee: Also attached: Information Disclosure Statement; Information Request; Nucleotide and/or Amino Acid Sequence Submission; Statement deleting Inventor(s) named in prior application; Statement deleting Inventor(s) named in prior application; 3 sheets of formal drawings; Abstract FILING FEE IS BASED ON CLAIMS AS FILED LESS ANY HEREWITH CANCELED Basic Filing Fee 710.00 Total effective claims 20 - 20 (at least 20) = 0 x \$ 18.00 \$ 0.00 Independent claims 1 - 3 (at least 3) = 0 x\$ 80.00 \$ 0.00 If any proper multiple dependent claims now added for first time, add \$270.00 (ignore improper) 0.00 SUBTOTAL 710.00 If "small entity," then enter half (1/2) of subtotal and subtract 0.001 SECOND SUBTOTAL 710.00 Assignment Recording Fee (\$40.00) 0.00 TOTAL FEE ENCLOSED \$ 710.00 Any future submission requiring an extension of time is hereby stated to include a petition for such time extension. The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached. 1100 North Glebe Road, 8th Floor **NIXON & VANDERHYE P.C.** Arlington, Virginia 22201-4714 By Atty: B. J. Sadoff, Reg. No. 36,663 Telephone: (703) 816-4000 Facsimile: (703) 816-4100 BJS:eaw Signature:

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Maertens Atty. Ref.: 620-149

Continuation of Serial No. **09/308,935** Group:

Filed: July 9, 2001 Examiner:

For: **PEPTIDE ANTAGONISTS OF DP TRANSCRIPTION** 

FACTORS

July 9, 2001

Assistant Commissioner for Patents Washington, DC 20231

Sir:

## **REQUEST**

The Office is requested to use the computer-readable copy of the Sequence Listing from the parent Application No. 09/308,935. The attached paper copy of the Sequence Listing is the same as the paper and computer-readable copies of the Sequence Listing filed in the parent Application No. 09/308,935, with the Letter dated December 23, 1999. No new matter has been added.

Respectfully submitted,

**NIXON & VANDERHYE P.C.** 

Ву:

**B. J. Sadoff** Reg. No. **36,663** 

BJS:eaw

1100 North Glebe Road, 8th Floor

Arlington, VA 22201-4714 Telephone: (703) 816-4000 Facsimile: (703) 816-4100